Please tell us about your clinical experience. How many patients with Uterine fibroids do you see yearly? How common are symptomatic treatments vs levonorgestrel intrauterine devices (where some studies reported substantial regression of fibroids) vs surgery?

How often do life-threatening complications occur, how many can be considered late complications of surgeries?

How efficient are oral contraceptive pills in reducing uterine bleeding and cramps? Do you see promise in any of the upcoming medications, in this regard?

What % of your patients fail first-line therapy?

Can you tell us your impressions on relugolix combination therapy (co-administration of relugolix 40 mg with estradiol 1.0 mg and norethindrone acetate 0.5 mg)? How do you see it’s potential use for the future?

In Phase 3, the company reported the following data:

• 78.4% of women who continued on relugolix combination therapy remained responders (menstrual blood loss < 80 mL) through Week 76 compared with 15.1% of women who discontinued treatment at Week 52 (p < 0.0001)

• 69.8% of women who continued relugolix combination therapy remained responders through Week 104
  
  
• 88.3% of women who discontinued treatment relapsed with heavy menstrual bleeding, on average 5.9 weeks after discontinuation

As for side effects, the company reports that bone mineral density was maintained through two years in the relugolix treatment arm. The most commonly reported adverse event in at least 10% of women treated with relugolix combination therapy was nasopharyngitis. Does any of this give you reason for worry or doubt? What are the adverse effects of treatments you've been previously using, and how does it compare to relugolix?

How likely would you be to prescribe relugolix in the event of an approval?